Ascletis Pharma Inc. (ASCLF)
Ascletis Pharma Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Hangzhou, ENG, CN. The stock last traded at $1.21, up 0.00% on the session, giving a market capitalisation of $1.26B. On trailing twelve-month figures it carries a trailing P/E of -25.00, a net margin of -17745.6%. Its beta of 0.38 implies it has historically moved less than the broad market.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.
Ascletis Pharma Inc. is most often compared with the following Healthcare names: